米托蒽醌和柔红霉素治疗急性髓系白血病临床比较  

Clinical Analysis of Mitoxantrone and Rubomycin in Treatment of Acute Myeloid Leukemia

作　　者：乔爱国[1] 杨丽华[1] 何吉琼 唐茂山[1] 

机构地区：[1]四川省达州市中心医院,四川达州635000

出　　处：《中国现代医生》2008年第24期50-51,共2页China Modern Doctor

摘　　要：目的比较米托蒽醌(MIT)和柔红霉素(DNR)治疗急性髓系白血病的临床效果。方法选择60例住院患者,随机分为两组,观察组采用MIT治疗方案,对照组采用DNR治疗方案,比较两组疗效、骨髓抑制程度和不良反应。结果观察组治疗总有效率为86.7%,对照组为70.0%,差异有统计学意义(P<0.05);观察组中、重度骨髓抑制发生率为100.0%,显著高于对照组的86.7%(P<0.05);观察组患者脱发和肺部感染发生率都要高于对照组,其他不良反应两组比较均无统计学差异(P>0.05)。结论对于急性髓系白血病的治疗,采用以米托蒽醌为主的化疗方案疗效明显优于以柔红霉素为主的化疗方案,值得临床推广。Objective To compare the clinical effect of mitoxantrone and rubomycin in treatment of acute myeloid leukemia. Methods 60 patients were divided into two groups. The observation group accepted MIT therapeutic scheme and the control group accepted DNR therapeutic scheme, their curative effect, marrow bate degree and adverse effects were compared. Results The total effective rate of observation group was 86.7%, which of the control group was 70.0%, the difference had statistical significance （P〈0.05）; the middle and bad marrow bate rate of observation was 100%, which was obviously high than the control group（P〈 0.05）; the incidence rate of alopecia and lung infection in observation group was higher than control group, other adverse effect in two groups had no statistical difference （P〉0.05）. Conclusion For acute myeloid leukemia,the MIT therapeutic scheme is better than the DNR therapeutic scheme, which can be widely used in clinic.

关 键 词：米托蒽醌 柔红霉素 急性髓系白血病 

分 类 号：R733.71[医药卫生—肿瘤]